期刊文献+

尿NGAL、Kim-1、L-FABP联合检测在糖尿病肾脏病早期诊断中的价值

下载PDF
导出
摘要 目的:探讨尿中性粒细胞明胶酶相关脂质转运蛋白(NGAL)、肾损伤因子-1(Kim-1)、肝型脂肪酸结合蛋白(L-FABP)联合检测在糖尿病肾脏病(DKD)早期诊断中的价值。方法:按照尿白蛋白肌酐比值(UACR)将2型糖尿病患者分为3组,Ⅰ组:糖尿病无肾病组(UACR<3 mg/mmol,n=50);Ⅱ组:早期DKD组(UACR 3~30 mg/mmol,n=50);Ⅲ组:临床DKD组(UACR>30 mg/mmol,n=50);同时选取50名健康体检者作为对照组。检测各组一般生化指标变化。ELISA法检测各组NGAL、Kim-1及L-FABP的表达,分析NGAL、Kim-1及L-FABP与UACR的相关性,ROC曲线比较不同指标单独及联合检测的诊断效能。结果:与对照组相比,糖尿病组的一般生化指标空腹血糖(FPG)、糖化血红蛋白(HbA1C)、血肌酐(Scr)、尿素氮(BUN)、胆固醇(TC)、三酰甘油(TG)均显著升高,差异有统计学意义(P<0.05)。与对照组相比,糖尿病各组KIM-1、L-FABP均依次增高,差异有统计学意义(P<0.05);糖尿病Ⅱ组和Ⅲ组NGAL较对照组比较亦明显增高,差异有统计学意义(P<0.05)。尿液NGAL、KIM-1及L-FABP水平与UACR均呈正相关(r=0.571,0.427,0.625;P<0.05)。尿液NGAL、KIM-1和L-FABP单独检测DKD灵敏度和特异度分别为63.3%、64.9%、67.2%和74.6%、79.8%、86.6%;三者联合诊断DKD的AUC值0.872,灵感度和特异度为77.4%和89.1%,均高于单独检测(P<0.05)。结论:NGAL、KIM-1、L-FABP是DKD的早期损伤标志物,联合检测对DKD的早期诊断具有重要临床应用价值。
出处 《中国中西医结合肾病杂志》 2023年第12期1096-1098,共3页 Chinese Journal of Integrated Traditional and Western Nephrology
基金 山西省卫生健康委科研项目(No.2018026) 吕梁市科技重点研发计划项目(No.2018shfz64-11)。
  • 相关文献

参考文献5

二级参考文献57

  • 1贾汝汉,高苹.糖尿病肾病肾小管间质病变研究进展[J].中国中西医结合肾病杂志,2005,6(6):311-314. 被引量:18
  • 2Gray SP, Cooper ME. Diabetic nephropathy in 2010: alleviating the burden of diabetic nephropathy[J]. Nat Rev Nephrol, 2011, 7(2): 71-73.
  • 3McMahor: BA, Murray PT. Urinary liver fatty acid-binding protein: another novel biomarker of acute kidney injury[J]. Kidney Int, 2010, 77(8): 657-659.
  • 4Fu WJ, Li BL, Wang SB, et al. Changes of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltration[J]. Diabetes Res Clin Pract, 2012, 95(1): 105-109.
  • 5Fu WJ, Xiong SL, Fang YG, et al. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study[J]. Endocrine, 2012, 41(1): 82-88.
  • 6Nielsen SE, Andersen S, Zdunek D, et al. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy[J]. Kidney Int, 2011, 79( 10): 1113-1118.
  • 7American Diabetes Association. Standards of medical care in diabetes-2012[J]. Diabetes care, 2012, 35 (Suppl 1): Sll-$63.
  • 8Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history[J]. Curr Diab Rep, 2006, 6(6): 479-483.
  • 9Nielsen SE, Schjoedt KJ, Astrup AS, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril[J]. Diabet Med, 2010, 27(10): 1144-1150.
  • 10Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease[J]. Curr Opin NephrolHypertens, 2008, 17(2): 127-132.

共引文献105

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部